Medicenna in the spotlight (part XI)
Re-evaluating the IL-2 thesis relative to recent Sanofi news
Medicenna (MDNA) has traded lower, going under $0.70 then back up again, on news that Sanofi wrote down their SAR’245 candidate (former THOR IL-2 asset) and discontinued ongoing Phase 2 trials. This comes just one quarter after Sanofi said they would decide on potential pivotal Phase 3 trials for SAR’245. These have been put on hold.
Sanofi’s IL-2 asset …